Skip to main content

Remote Job Finders (RJF)

Lilly’s tirzepatide will be biggest blockbuster ever, topping $70B by 2032: Evaluate

Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.

BIO 2026: Biopharma dealmakers seek to protect ‘premium pricing’ from Trump’s MFN policy

With drug pricing now embedded in U.S. policy, business development teams in biotech and pharma are changing the way they strike deals, including acknowledging policy uncertainties with renegotiation clauses.

With onshoring ‘having a moment,’ Aquestive CEO shares lessons from 20 years of US manufacturing

Having stuck with local production in the years when offshoring to lower-cost locations was in fashion, Aquestive’s CEO is well placed to explain what the recent reshoring drive means for manufacturers.
Scroll to top